Yes, MDS is Absolutely Possible Without Cytogenetic Abnormalities
MDS can definitively occur in the absence of detectable cytogenetic abnormalities, affecting 20-70% of patients depending on the subtype and whether the disease is de novo or therapy-related 1, 2, 1. These patients represent a distinct clinical entity that requires careful morphologic assessment and often molecular testing to establish the diagnosis.
Understanding the Cytogenetic Landscape in MDS
While clonal chromosomal abnormalities are observed in 30% to >80% of MDS patients 1, the substantial proportion with normal karyotypes does not exclude MDS. In these cytogenetically normal cases, sub-microscopic alterations including point mutations, microdeletions, micro-amplifications, epigenetic changes, or copy-number neutral loss (such as uniparental disomy) provide the genetic basis for the disease 1, 2, 1.
Key Diagnostic Principles
The diagnosis of MDS in patients with normal cytogenetics relies on:
- Morphologic criteria: Unequivocal dysplasia in ≥10% of cells from at least one myeloid lineage in the bone marrow 3
- Clinical context: Appropriate clinical setting with persistent unexplained cytopenias
- Exclusion criteria: Other causes of secondary dysplasia must be ruled out 3
Molecular Evidence of Clonality
Even in the absence of cytogenetic abnormalities, MDS remains a clonal disorder 4. Research using X-linked restriction fragment length polymorphism analysis demonstrated monoclonal patterns in MDS patients with normal karyotypes, confirming the clonal nature of the disease even without visible chromosomal changes 4.
Recent molecular studies show that acquired mutations are present in approximately 90% of MDS cases 2. The most frequent mutations occur in:
- Epigenetic regulators: TET2 (15-25%), ASXL1 (10-20%), DNMT3A (10%), IDH1/2 (5-10%)
- Splicing factors: SF3B1 (15-30%), SRSF2 (10-15%), U2AF1 (5-10%)
- Transcription factors: RUNX1 (10-15%), TP53 (5-10%)
- Signaling molecules: NRAS/KRAS (10%) 2, 1
Diagnostic Approach for Cytogenetically Normal Cases
When cytogenetics are normal or non-informative, the diagnostic workup should proceed as follows:
Mandatory assessments 5:
- Peripheral blood smear with evaluation of dysplasia and blast enumeration
- Bone marrow aspirate with assessment of dysplasia in all lineages, blast count, and ring sideroblast enumeration
- Bone marrow biopsy for cellularity, fibrosis, and topography assessment
- Standard cytogenetic analysis (20-25 metaphases analyzed)
Recommended additional testing 1:
- FISH analysis if standard cytogenetics fails or is insufficient
- Somatic mutation analysis, particularly when MDS is uncertain (especially in ICUS or IDUS cases with normal karyotype)
- Flow cytometry immunophenotyping (though abnormalities alone are not diagnostic)
Critical Diagnostic Challenges
The diagnosis becomes particularly difficult in patients with normal karyotype who lack robust morphologic markers (such as ring sideroblasts or excess blasts) 5. In these scenarios:
- If only unilineage dysplasia is present
- No increase in blasts in peripheral blood or bone marrow
- Ring sideroblasts <15% of erythroid precursors
- No recurrent cytogenetic abnormalities present
An observation period of 6 months with repeat bone marrow investigation is recommended before making the diagnosis of MDS 5. These patients typically present with mild cytopenia only, and rapid disease progression is unlikely.
Recent Clinical Insights
A 2026 study found that approximately 20% of MDS patients lack both gene mutations and cytogenetic abnormalities 6. These patients were characterized by:
- Younger age
- Female predominance
- Lower IPSS-R/IPSS-M risk
- Most favorable survival outcomes
- Distinct immune-metabolic transcriptional programs (versus inflammatory/proliferative signatures in genomically altered disease)
This suggests that mutation-negative/normal-karyotype MDS represents a biologically distinct low-risk subgroup 6.
Common Pitfalls to Avoid
Do not rely solely on flow cytometry: Flow cytometry abnormalities are not diagnostic of MDS in the absence of morphologic and/or cytogenetic findings 3, 7
Do not dismiss the diagnosis based on normal cytogenetics alone: The absence of cytogenetic abnormalities does not exclude MDS if morphologic criteria are met
Beware of alternative diagnoses: In patients with non-informative genetic profiles, carefully exclude aplastic anemia, drug/radiation toxicity, autoimmune diseases, and other conditions 8
Consider clonal hematopoiesis of indeterminate potential (CHIP): The presence of mutations alone without morphologic dysplasia may represent CHIP rather than MDS 9
Prognostic Implications
While cytogenetics carries the highest prognostic weight in the IPSS-R scoring system 1, 2, patients with normal karyotypes fall into an intermediate-risk category 3. However, the specific molecular profile significantly influences prognosis, with certain mutations (particularly TP53, RUNX1) conferring worse outcomes even in the absence of cytogenetic abnormalities.